Propentofylline in the treatment of Alzheimer's disease and vascular dementia: A review of phase III trials

Dementia and Geriatric Cognitive Disorders

Volumn 9, Issue SUPPL. 1, 1998, Pages 36-43

  Rother, Matthias ^a,e   Erkinjuntti, Timo ^b   Roessner, Martin ^a   Kittner, Barbara ^a   Marcusson, Jan ^c   Karlsson, Ingvar ^d  

^a SANOFI   (France)

^b UNIVERSITY OF HELSINKI   (Finland)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e CNS Disease Group   (United States)

Author keywords

Alzheimer's disease; Astrocyte; Microglia; Propentofylline; Vascular dementia

Indexed keywords

CYTOKINE; FREE RADICAL; GLUTAMIC ACID; PROPENTOFYLLINE; VASODILATOR AGENT;

ALZHEIMER DISEASE; CELL ACTIVATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLIA CELL; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; VERTIGO;

ALZHEIMER DISEASE; CLINICAL TRIALS, PHASE III; DEMENTIA, VASCULAR; HUMANS; NEUROPROTECTIVE AGENTS; XANTHINES;

EID: 0031866396     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051188     Document Type: Conference Paper

References (26)

1. Goldman J, Côté L: Aging of the brain: Dementia of the Alzheimer's type; in Kandel ER, Schwartz JH, Jessell TM (eds): Principles of Neural Science. Norwalk, Appleton and Lange, 1991, pp 974-983.
2. Beal M, Flint M: Mechanisms of excitotoxicity in neurologic diseases. FASEB J 1991;6:3338-3344.
3. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW: Cytotoxicity of microglia. Glia 1993; 7:111-118.
4. McGeer P, Roger J: Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 1992;42:447-449.
5. Siesjö BK: Pathophysiology and treatment of focal brain ischemia. II. Mechanisms of damage and treatment. J Neurosurg 1992;7:337-354.
6. Si QS, Nakamura Y, Schubert P, Rudolphi K, Kataoka K: Adenosine and propentofylline inhibit the proliferation of cultured microglial cells. Exp Neurol 1996;137:345-349.
7. Banati RB, Schubert P, Rothe G, Gehrmann J, Rudolphi K, Valet G, Kreutzberg GW: Modulation of intracellular formation of reactive oxygen intermediates in peritoneal macrophages and microglia/brain macrophages by propentofylline. J Cereb Blood Flow Metab 1994;14: 145-149.
8. Shinoda I, Furukawa Y, Furukawa S: Stimulation of nerve growth factor synthesis/secretion by propentofylline in cultured mouse astroglial cells. Biochem Pharmacol 1990;39:1813-1816.
9. Nabeshima T, Nitta A, Hasegawa T: Impairment of learning and memory and the accessory symptom in aged rat as senile dementia model. 3 Oral administration of propentofylline produces recovery of reduced NGF content in the brain of aged rats. Jpn J Psychopharmacol 1993;13:89-95.
10. Nitta A, Ogihara Y, Onishi J, Hasegawa T, Furukawa S, Nabeshima T: Propentofylline prevents neuronal dysfunction induced by infusion of anti-nerve growth factor antibody into the rat septum. Eur J Pharmacol 1996;307: 1-6.
11. Fuji K, Hiramatsu M, Kameyama T, Nabeshima T: Effects of repeated administration of propentofylline on memory impairment produced by basal forebrain lesion in rats. Eur J Pharmacol 1993;236:411-417.
12. Goto M, Demura N, Sakaguchi T: Effects of propentofylline on disorder of learning and memory in rodents. Jpn J Pharmacol 1987;45: 373-378.
13. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. DSM-III-R, ed 3, rev. Washington, Am Psychiatr Assoc 1987, pp 97-126.
14. Folstein MF, Folstein SE, McHugh PR: 'Minimental state': A practical method for grading the cognitive state of patients for clinician. J Psychiatr Res 1975;12:189-198.
15. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RW, Symon L: Cerebral blood flow in dementia. Arch Neurol 1975;32:632-637.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Standlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-949.
17. Roman GC, Tatemichi TK, Erkinjuntti T, et al: Vascular dementia: Diagnostic criteria for research studies. Report of the MINDS/AIREN International Workshop. Neurology 1993;43: 250-260.
18. Marcusson J, Rother M, Kittner B, Rossner M, Smith RJ, Babic T, Folnegovic-Smakc V, Moller HJ, Labs KH: A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dement Geriatr Cogn Disord 1997;8:320-328.
19. Gottfries CG, Bråne G, Gullberg B, Steen G: A new rating scale for dementia syndromes. Arch Gerontol Geriatr 1982;1:311-330.
20. Clinical global impressions; in Association for Methodology and Documentation of Psychology and Collegium Internationale (Psychiatriae Scalarum) (eds): Rating Scales for Psychiatry. Weinheim, Beltz Test GmbH, 1990.
21. Overall JE, Schaltenbrand R: The SKT neuropsychological test battery. J Geriatr Psychiatr Neurol 1992;5:220-227.
22. Fleischmann UM, Oswald WD: Nürnberger-Alters-Inventar (NAI)-Kurzmanual: Testbeschreibung, Testkriterien, Normwerte. Nürnberg, Universität Erlangen-Nürnberg, 1986.
23. Reisberg B, Ferris SH, Borenstein J, Simaiko E, de Leon MJ, Buttinger C: Assessment of presenting symptoms; in Poon LW (ed): Handbook for Clinical Memory Assessment of Older Adults. Hyattsville, American Psychological Association, 1986, pp 108-128.
24. European Propentofylline Study Group: Benefits of propentofylline therapy persist after drug withdrawal: Results of a double-blind, placebo-controlled study. Am Geriatr Soc/Am Fed Aging Res Annu Meet, Seattle, May 1998.
25. Kittner B, Roessner M, Rother M: Clinical trials in dementia with propentofylline. Ann NY Acad Sci 1997;826:307-316.
26. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT and the Donepezil Study Group: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.